Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. The company also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. It sells its products through specialty pharmacy and distributor networks. The company has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.…
Puma Biotechnology Inc (PBYI) (Q3 2026) Earnings Call Highlights: Debt-Free and Raising ...
Puma Biotechnology (NASDAQ: PBYI) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 179 employees.
The shares were at 7.050 USD on 20 November 2026, up 43.9% over 52 weeks. Its 52-week range is 4.580 USD to 11.50 USD: the price is 38.7% below the high and 53.9% above the low.
At a market capitalisation of 364.47M USD, it trades at 15.3 times trailing earnings and 20.1 times forward earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.1, a discount of 54% for PBYI.
Puma Biotechnology reports return on equity of 23.9%, an operating margin of 11.3% and revenue up 1.1% year over year.
It holds more cash than debt, a net cash position of 103.71M USD. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. The next earnings report is expected on 25 February 2027.